Are you looking how to identify, grow, optimise, and substantiate the health benefits of  your probiotics and live biotherapeutic products?  NIZO has helped many companies to identify, grow, optimise, and substantiate the health benefits of probiotics and live biotherapeutic products. We have carried out hundreds of fermentation and media optimisation projects, as well as a broad range of strict anaerobic productions, tech transfers, and successful clinical trials.

In this on demand webcast it will be explained how we use robust and science-based methods that provide a knowledge-driven-selection and assessment of bacterial strains, optimised production of microorganisms, and investigation and substantiation of the health benefits.

Our Webcasts

NIZO Webcast: The probiotic journey, from discovery to health benefit substantiation

Coming soon...

NIZO Dairy webcast series about Food Safety and Chain Control

Coming soon...

NIZO Dairy webcast series about Health Benefits

Coming soon...

NIZO Dairy webcast series about the Protein Transition

The market for probiotics and live biotherapeutic products continues to grow, as we increase our understanding of how they can improve health. Probiotic and pharmaceutical companies are looking for ways to use the naturally occurring bacteria in our bodies to amend dysbiosis of the gut, skin and more. Then they must get their products to market, quickly and cost-effectively. But there are many challenges that will define a company’s success or failure – especially when working with living organisms, that don’t always behave the way we want.  

In a virtual presentation, Janneke Ouwerkerk, Group Leader Food Safety & Fermentation, and Ioana Iorga, Business Development Manager, explain NIZO’s multidisciplinary and multi-stage approach in the probiotic journey, from discovery to health benefit substantiation.

The following topics are discussed:

  • Select the most suitable and promising strains for probiotics by NIZO’s state-of-the-art bioinformatics.
  • Design a process to produce viable bacteria in large quantities.
  • Optimise conditions and move up to full anaerobic scaling: from 40 litres to 600 litres.
  • Provide robust inside to which bacterial strains are most promising for costly clinical trials by in vitro testing.
Any questions?

Ioana Iorga is happy to answer all your questions.

More about Ioana Meet Ioana